Brokers and banks usually stop taking bids earlier. Check the exact time with yours.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Funding working capital requirements of the company
Allocation of funds to manage inventory, trade receivables, and operational expenses arising from expanding diagnostic reagent and equipment distribution.
Repayment or prepayment of outstanding borrowings
Repayment of existing term loans and credit facilities to reduce financial leverage and debt servicing costs.
General corporate purposes
Funding strategic growth initiatives, business development, operational enhancements, and unforeseen corporate contingencies.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
No peer comparisons added yet.
Q-Line Biotech Limited, established in 2010 and originally incorporated as POCT Services Private Limited, is an Indian healthcare diagnostics company operating in the in-vitro diagnostics (IVD) sector. The company specializes in the development, indigenous manufacturing, and commercialization of a broad spectrum of diagnostic reagents, rapid test kits, point-of-care (POC) devices, and automated diagnostic analyzers. Its comprehensive product portfolio spans clinical chemistry, hematology, immunodiagnostics, and molecular diagnostic solutions tailored for healthcare providers, diagnostic laboratories, and medical institutions across India. The company operates state-of-the-art manufacturing facilities located in Lucknow and New Delhi, supported by dedicated research and development capabilities focused on product innovation, reverse engineering, and stringent quality control. Q-Line Biotech employs a distribution-led business model, combining its internal manufacturing output with the import and domestic distribution of specialized diagnostic equipment. Through an established pan-India logistics and distribution network, the firm supplies hospital networks, pathology labs, medical colleges, and government health agencies. Headquartered in Lucknow, Uttar Pradesh, the company transitioned from a private entity into a public limited enterprise in March 2025 prior to making its public market debut on the NSE Emerge platform in May 2026. Led by an experienced management team with over two decades of industry expertise, Q-Line Biotech has positioned itself as an integrated IVD player benefiting from growing domestic demand for accessible healthcare testing, diagnostic automation, and localized medical device manufacturing.
Q-Line Biotech raised Rs. 61.09 crore from 18 anchor investors on May 20, 2026, allocating 17,81,200 equity shares at Rs. 343 per share, with major participation from Abakkus Mutual Fund, Carnelian AIF, Sanshi Fund-I, Bharat Venture Opportunities Fund, India Max Investment Fund, Tiger Strategies Fund, and HDFC Bank Limited.
Source: RHP • Analysis provided for informational purposes
Last Updated: 24 August 2026, 5:23 PM
In-House Manufacturing and Research Capabilities
The company maintains dedicated production units and internal R&D infrastructure capable of developing diverse diagnostic reagents and point-of-care testing equipment.
Comprehensive Diagnostic Product Line
Q-Line offers an extensive range of IVD products spanning hematology, clinical chemistry, immunodiagnostics, and automated lab machinery.
Integrated Distribution Network
A nationwide distribution setup allows the firm to effectively supply diagnostic laboratories, hospitals, and medical colleges across India.
Experienced Promoter Leadership
The core management team possesses over two decades of operational experience in medical diagnostics and healthcare logistics.
Customer and Entity Concentration Risk
A major portion of historical sales is concentrated among top institutional clients and specific promoter-affiliated distribution partners.
Working Capital and Cash Flow Pressures
Expanding operations have required significant working capital, leading to elevated inventory holding periods and trade receivables.
Competitive Diagnostic Market
The Indian IVD sector is highly fragmented and competitive, exposing the company to pricing pressures and rapid technological shifts.
Q-Line Biotech Limited
298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh - 226012
View on Maps →Purva Sharegistry (India) Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Regulatory and Compliance Requirements
Operations remain subject to stringent quality standards and evolving domestic regulations governing medical devices and diagnostic reagents.